Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

As of Friday, December 12, Lantheus Holdings, Inc.’s LNTH share price has surged by 5.44%, which has investors questioning if this is right time to sell.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated ...

The 4 immuno-oncology stocks we track reported a stunning Q3. As a group, revenues beat analysts’ consensus estimates by 8.4%. Luckily, immuno-oncology stocks have performed well with share prices up ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Share.Market's CRISP® Scorecard for September 2025 urges investors to focus on mutual fund consistency and risk management ...

Learn more about whether Immunocore Holdings plc or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ ...

An update from Sanofi ( ($SNY) ) is now available. On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved ...